ARCT
Arcturus Therapeutics Holdings Inc.7.13
-0.12-1.66%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
CF study details dominate Q&A
Q&A drilled into ARCT-032 CF study optimizations like stable baselines, sensitive LCI endpoint, and international sites in Europe/Middle East for faster Class I enrollment, adding execution color to prepared remarks. Management detailed starting Cohort 4 at 10mg after 4-of-6 patients showed mucus plug reductions, with flexibility to 15mg. Four of six responded on mucus plugs. OTC discussions seek Type C clarity on bifurcated adult/pediatric paths but remained non-specific. CSL partnership talks active amid U.S. hurdles. Tone stayed confident on milestones; investors eye 2026 CF data.
Key Stats
Market Cap
202.58MP/E (TTM)
-Basic EPS (TTM)
-2.46Dividend Yield
0%Recent Filings
8-K
ARCT-032 advances; cash to 2028
Arcturus reported Q4 and FY 2025 results on March 3, 2026, with revenue dropping to $7.2M and $82.0M from prior-year peaks due to CSL collaboration normalization, yet slashed operating expenses to $38.5M and $158.3M, narrowing FY net loss to $65.8M. ARCT-032 cleared safety review for 12-week Phase 2 in H1 2026; cash runway hits Q2 2028. Progress fuels rare disease push.
10-K
FY2025 results
Arcturus Therapeutics posted FY2025 results with $82M revenue, down 46% y/y from CSL milestones and supply deals as KOSTAIVE shifted to commercialization in Japan post-Q4 2024 launch, while Q4 saw Phase 2 momentum in CF (ARCT-032 interim data) and OTC (ARCT-810 dosing advances). R&D fell 43% to $112M, reflecting lower COVID manufacturing yet higher CF clinical costs; G&A dropped 13% on headcount cuts. Cash burned $74M in operations but ended at $231M, bolstered by $39M CSL payments amid arbitration over EU approval milestone. Q4 platform tweaks accelerated rare disease progress. CSL's $430M write-down clouds vaccine royalties.
8-K
CFO resigns; interim named
Arcturus Therapeutics' CFO Andy Sassine and board member resigned amicably on December 11, 2025, with employment ending December 31; no disagreements noted. Controller Joe Roberts, 43, stepped in as interim principal financial and accounting officer on December 12. Separation includes $572,000 lump-sum severance. Smooth transition, yet leadership shift tests continuity.
10-Q
Q3 FY2025 results
Arcturus Therapeutics posted Q3 revenue of $17.2M, down 59% y/y from $41.7M (derived), mainly as CSL Seqirus collaboration revenue fell with KOSTAIVE shifting to commercial phase; YTD revenue dropped 42% to $74.8M. R&D expenses plunged 41% y/y to $23.3M, trimming operating loss to $16.5M from $10.7M while net loss widened to $13.4M or $(0.49) diluted EPS, reconciled to 27.2M shares. Cash burned $58M in operating activities, leaving $180.4M in cash equivalents plus $55M restricted and $50M undrawn Wells Fargo revolver to April 2026. Expenses align across quarters. Cash lasts the year.
8-K
Q3 loss widens; CF data shines
Arcturus reported Q3 revenue of $17.2M, down sharply from prior year due to lower CSL collaboration activity, with net loss widening to $13.5M on $33.7M operating expenses—yet R&D cuts slashed costs 41%. Phase 2 ARCT-032 interim data showed mucus burden reductions in 4/6 CF patients after 28 days; 12-week study starts H1 2026. Cash at $237.3M funds into 2028.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ARTV
Artiva Biotherapeutics, Inc.
4.55-1.75
CDTX
Cidara Therapeutics, Inc.
220.05-0.05
MRNA
Moderna, Inc.
29.89-0.03
MTNB
Matinas Biopharma Holdings, Inc
0.74+0.01
OCEA
Ocean Biomediacal, Inc.
0.00+0.00
OSRH
OSR Holdings, Inc.
0.55-0.02
VIR
Vir Biotechnology, Inc.
6.48-0.24
VXRT
Vaxart, Inc.
0.37+0.01
XRTX
XORTX Therapeutics Inc.
0.59-0.01